Platelets, Cardiac Valves and Sulphinpyrazone

Thromb Haemost 1982; 47(02): 189
DOI: 10.1055/s-0038-1657163

Letter to the Editor

Schattauer GmbH Stuttgart

E A Loeliger

Interne Geneeskunde, Academisch Ziekenhuis Leiden, The Netherlands

References
1 Ludlam CA, Allan N, Blandford RB, Dowdle R, Bentley NJ, Bloom AL. Platelet and coagulation function in patients with abnormal cardiac valves treated with Sulphinpyrazone. Thromb Haemostas 1981; 46: 743-746
2 Blackburn EK. Long-term anticoagulant therapy. Prescribers’ J 1976; 16: 73-74
3 Barkhan P. Therapeutic range with BCTR (letter). Thromb Haemostas 1976; 35: 751
4 Loeliger EA. The optimal therapeutic range in oral anticoagulation. History and Proposal. Thromb Haemostas 1979; 42: 1141-1152
5 Steele P, Rainwater J. Favorable effect of sulfinpyrazone on thromboembolism in patients with rheumatic heart disease. Circulation 1980; 62: 462-465
6 Loeliger EA. Sulfinpyrazone and Thromboembolism (letter). Circulation 1981; 64: 1076-1077